Assessment of the Efficacy of Topical Curcumin in Treatment of Oral Lichen Planus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to evaluate the therapeutic impact of curcumin as Alternative or Complementary to Triamcinolone Acetonate in Treatment of Oral Lichen Planus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients

NCT03877679

Oral Lichen Planus

UNKNOWN PHASE1

Different Treatment Modalities for Oral Lichen Plan

NCT06681090

Oral Lichen Planus

COMPLETED PHASE1

Evaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen Planus

NCT05951361

Erosive Oral Lichen Planus

COMPLETED NA

Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus With Immunohistochemical Analysis

NCT05882864

Oral Lichen Planus

UNKNOWN PHASE4

A Randomized, Placebo-controlled, Double-blind Clinical Trial of Curcuminoids in Oral Lichen Planus

NCT00226174

Oral Lichen Planus

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Oral lichen planus (OLP) is a chronic inflammatory disorder affecting the mucous membranes, believed to be an immune-mediated condition. Its persisting nature can lead to extended discomfort for those affected. The primary symptoms are pain and a burning sensation, with a potential risk of malignancy if not properly managed, necessitating lifelong clinical monitoring. Presently, OLP is considered a significant challenge due to the absence of a definitive cure.

Patients \& patients: Thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline,1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline,1and 3 months' evaluation periods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Lichen Planus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline, 2, weeks and 1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline, 1 and3 months' evaluation periods.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical triamcinolone acetonide

Group I

Group Type EXPERIMENTAL

topical triamcinolone acetonide

Intervention Type DRUG

ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks

Topical curcumin

Group II

Group Type EXPERIMENTAL

Topical Curcumin

Intervention Type DRUG

Ten patients with OLP received topical curcumin four times per day for six weeks.

Topical triamcinolone acetonide combiend with topical curcumin

Group III

Group Type ACTIVE_COMPARATOR

topical triamcinolone acetonide combiend with topical curcumin

Intervention Type DRUG

Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

topical triamcinolone acetonide

ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks

Intervention Type DRUG

Topical Curcumin

Ten patients with OLP received topical curcumin four times per day for six weeks.

Intervention Type DRUG

topical triamcinolone acetonide combiend with topical curcumin

Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Group I Group II Group III

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of OLP

Exclusion Criteria

* Any systemic autoimmune disease
* Any current use of anticoagulant or antiplatelet agents (curcumin has inhibitory effects on platelet aggregations).
* Any topical, local or systemic corticosteroids therapy during the past 3 months.
* lichenoid reaction from medications.
* Pregnant or lactation women.
* smokers

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No